MTX1

Metaxin-1 · Q13505 · MTX1 on Sugi Atlas →

0 patent compounds predicted against MTX1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MTX1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Methotrexate in Patients with Early Rheumatoid Arthritis PHASE4ACTIVE_NOT_RECRUITING
Immune Modulation During Palynziq® Treatment in Adults (IMPALA) PHASE4RECRUITING
Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis PHASE4COMPLETED
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis PHASE3COMPLETED
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations PHASE3RECRUITING
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma PHASE3UNKNOWN
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia PHASE3UNKNOWN
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer PHASE3COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia PHASE3COMPLETED
An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis PHASE2COMPLETED
An Adaptive Design Study of MTX228 PHASE2RECRUITING
WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease PHASE2UNKNOWN
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) PHASE2RECRUITING
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease PHASE2RECRUITING
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction PHASE1COMPLETED
Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis PHASE1NOT_YET_RECRUITING
Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients PHASE1COMPLETED
A First-in-Human Safety Trial of MTX-474 PHASE1COMPLETED
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients PHASE1RECRUITING
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma EARLY_PHASE1ACTIVE_NOT_RECRUITING
Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL nanCOMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL nanCOMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia nanCOMPLETED
Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate nanCOMPLETED
Study for Treatment of Cancer in Children With Ataxia-telangiectasia nanCOMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient nanRECRUITING
Methotrexate Monitoring Target Trial Emulation nanCOMPLETED
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia nanCOMPLETED
Microbial Dysbiosis in Rheumatoid Arthritis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MTX1 binder may also engage these)

ProteinNameSimilarity
PML Protein PML 0.960 landscape →
Q96NA8 0.958 Q96NA8 →
Q6GQT6 0.957 Q6GQT6 →
P97260 0.956 P97260 →
A2RRU4 0.956 A2RRU4 →
Q32KT5 0.956 Q32KT5 →
Q8C4U2 0.956 Q8C4U2 →
A6QM06 0.955 A6QM06 →
Q5MNU5 0.955 Q5MNU5 →
Q69Z89 0.954 Q69Z89 →
Q12770 0.954 Q12770 →
P41155 0.954 P41155 →
Q5SQH8 0.954 Q5SQH8 →
Q8N554 0.953 Q8N554 →
Q96G42 0.953 Q96G42 →
X6R8R1 0.952 X6R8R1 →
Q66T02 0.951 Q66T02 →
E1BBQ2 0.951 E1BBQ2 →
Q8CE64 0.950 Q8CE64 →
Q8N1F8 0.950 Q8N1F8 →
Q70EL4 0.949 Q70EL4 →
A6QNS9 0.949 A6QNS9 →
Q96JH8 0.949 Q96JH8 →
Q5QP82 0.948 Q5QP82 →
RASSF5 Ras association domain-containing protein 5 0.948 landscape →
Q80UW0 0.948 Q80UW0 →
Q9H607 0.948 Q9H607 →
STK35 Serine/threonine-protein kinase 35 0.947 landscape →
Q9BZ19 0.947 Q9BZ19 →
Q9BT49 0.947 Q9BT49 →